Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Blueprint Medicines (BPMC) Tops Q4 EPS by 1c
March 9, 2017 7:08 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.75), $0.01 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $5.87 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More